Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SB 1481Session 2025-2026

An Act providing for reimbursement claims methodology and for safety net reimbursement protection; providing for safety net prescription drug distribution and access protections; imposing duties on the Department of Human Services, Insurance Department and Office of Attorney General; and imposing penalties.

Printer's No. PN1965

See other bills
under the
same topic PRINTER'S NO. 1965 THE GENERAL ASSEMBLY OF PENNSYLVANIASENATE BILL No.1481 Session of 2026 INTRODUCED BY BROOKS, BARTOLOTTA, KEARNEY, VOGEL, BROWN, J. WARD AND KANE, SEPTEMBER 25, 2026 REFERRED TO HEALTH AND HUMAN SERVICES, SEPTEMBER 25, 2026 AN ACTProviding for reimbursement claims methodology and for safety net reimbursement protection; providing for safety net prescription drug distribution and access protections; imposing duties on the Department of Human Services, Insurance Department and Office of Attorney General; and imposing penalties.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. Short title.This act shall be known and may be cited as the Safety Net Nondiscrimination Act.Section 2. Definitions.The following words and phrases when used in this act shall have the meanings given to them in this section unless the context clearly indicates otherwise:"340B drug." A drug that is a covered outpatient drug within the meaning of section 340B of the Public Health Service Act that is required to be offered to covered entities at reduced prices by a manufacturer under section 340B of the Public Health Service Act and is purchased by a covered entity. For purposes 1234567891011121314151617181920 of this definition, a drug shall be considered purchased by a covered entity if it would have been purchased but for a violation of section 6."Contract pharmacy." A pharmacy that is contracted by a covered entity to provide services to and on behalf of the covered entity with respect to 340B drugs purchased by the covered entity."Covered entity." An entity described in section 340B(a)(4) of the Public Health Service Act participating or authorized to participate in the program described in section 340B of the Public Health Service Act."Covered insurer." The following:(1) A Medicaid managed care organization or entity that reimburses covered entities or contract pharmacies for prescription drugs or dispensing services on behalf of patients, including an entity that holds a valid license by the Insurance Department with authority to issue a health insurance policy and governed under any of the following:(i) The act of May 17, 1921 (P.L.682, No.284), known as The Insurance Company Law of 1921, including section 630 and Article XXIV of that act.(ii) The act of December 29, 1972 (P.L.1701, No.364), known as the Health Maintenance Organization Act.(iii) 40 Pa.C.S. Ch. 61 (relating to hospital plan corporations) or 63 (relating to professional health services plan corporations).(2) The term does not include any of the following:(i) A medical assistance fee-for-service program under Article IV of the act of June 13, 1967 (P.L.31, 20260SB1481PN1965 - 2 - 123456789101112131415161718192021222324252627282930 No.21), known as the Human Services Code.(ii) An individual paying for drugs on the individual's own behalf or on behalf of another individual.(iii) The Pennsylvania Employees Benefit Trust Fund or any successor organization that only provides prescription drug benefits for employees of the Commonwealth and their covered dependents.(iv) The Special Pharmaceutical Benefits Program operated by the department."Department." The Department of Human Services of the Commonwealth."Drug." As defined in section 2 of the act of September 27, 1961 (P.L.1700, No.699), known as the Pharmacy Act."Insurance Department." The Insurance Department of the Commonwealth."Mail delivery." Dispensing or delivering medications by mail, courier or shipping service."Manufacturer." As defined in section 2 of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act. The term includes a manufacturer of biological products."Medicaid managed care organization." A medical assistance managed care organization as defined in section 449.2 of the Human Services Code."Package." An individual saleable unit as defined under 21 U.S.C. § 360eee(11)(B) (relating to definitions)."Pharmacy." As defined in section 2 of the Pharmacy Act."Pharmacy benefit manager." As defined in section 103 of the act of November 21, 2016 (P.L.1318, No.169), known as the 20260SB1481PN1965 - 3 - 123456789101112131415161718192021222324252627282930 Pharmacy Benefit Reform Act."Public Health Service Act." The Public Health Service Act (58 Stat. 682, 42 U.S.C. § 201 et seq.)."Sexually transmitted disease clinic." A covered entity or entity eligible to become a covered entity that receives support from the department under a Participating Provider Agreement funded under section 318 of the Public Health Service Act as of the effective date of this definition or at any time thereafter."Third-party logistics provider." An entity that provides or coordinates warehousing or other logistics services for a drug manufacturer but does not take ownership of the drug or have responsibility to direct the sale or disposition of the drug.Section 3. Discriminatory pharmacy reimbursement prohibited.(a) Payment.--Neither a pharmacy benefit manager nor a covered insurer that reimburses a covered entity or a contract pharmacy for drugs under a contract, or any agent acting on behalf of a pharmacy benefit manager or covered insurer, shall pay the covered entity or contract pharmacy less than:(1) the national average drug acquisition cost as described in 42 U.S.C. § 1396r-8(f) (relating to payment for covered outpatient drugs) for 340B drugs; or(2) the wholesale acquisition cost as specified in 42 U.S.C. § 1395w-3a(c)(6)(B) (relating to use of average sales price payment methodology) for 340B drugs that do not have a defined national average drug acquisition cost.(b) Waiver.--Notwithstanding subsection (a), a covered entity shall have the sole discretion to voluntarily agree to waive the protections in this section, provided that a person may not obtain a waiver through means of any direct or indirect coercion. A covered entity may withdraw a waiver upon reasonable 20260SB1481PN1965 - 4 - 123456789101112131415161718192021222324252627282930 notice.Section 4. Reimbursement claims methodology.The department, a covered insurer, a pharmacy benefit manager or any other entity that administers or manages prescription drug benefits on behalf of the department or a Medicaid managed care organization, shall rely exclusively on a claims-level methodology involving the use of a nationally recognized billing modifier for identifying drugs purchased under section 340B of the Public Health Service Act when paying for drugs on behalf of Medicaid to ensure that claims for the drugs are removed from the encounter data required under section 42 U.S.C. § 1396b(m)(2)(A)(xiii) (relating to payment to States) and excluded from Medicaid drug rebate requests.Section 5. Safety net reimbursement protection.(a) Prohibitions.--A Medicaid managed care organization, a pharmacy benefit manager or other entity administering or managing prescription drug benefits on behalf of a Medicaid managed care organization may not:(1) prevent a covered entity or contract pharmacy from administering or dispensing 340B drugs by any legal means, including mail delivery, or submitting a claim for reimbursement for 340B drugs or decline to cover a claim for reimbursement for administered or dispensed 340B drugs because the drug was purchased under section 340B of the Public Health Service Act;(2) impose a limitation on the distance between the covered entity and contract pharmacy or between the covered entity or contract pharmacy and the patient; or(3) except as necessary to comply with Federal or State law or to prevent a duplicate discount prohibited under 20260SB1481PN1965 - 5 - 123456789101112131415161718192021222324252627282930 Federal law, request, require or compel the transmission of any ingredient cost, pricing data or other data pertaining to the program established under section 340B of the Public Health Service Act as a condition of reimbursement or participation.(b) Effect of violation.--Any rule, regulation or statement of policy in violation of this section shall be null and void.(c) Outpatient prescription drugs.--The department shall maintain coverage for all outpatient prescription drugs through Medicaid managed care organizations for as long as any medical assistance services described in 42 U.S.C. § 1396d(a) (relating to definitions) are delivered by any Medicaid managed care organization.(d) Grants for sexually transmitted disease clinics.--The department shall ensure that:(1) no later than 90 days after the effective date of this paragraph each sexually transmitted disease clinic shall receive a grant of at least $500 from the department's Federal funding under section 318 of the Public Health Service Act to perform sexually transmitted disease testing and treatment; and(2) all new awards or renewals provided to sexually transmitted disease clinics shall provide for a grant of at least $500 from the department's Federal funding under section 318 of the Public Health Service Act to perform sexually transmitted disease testing and treatment.Section 6. Safety net prescription drug distribution and access protections.(a) Acquisitions.--A manufacturer, or an agent or affiliate of a manufacturer, or third-party logistics provider may not, 20260SB1481PN1965 - 6 - 123456789101112131415161718192021222324252627282930 either directly or indirectly, deny, restrict, prohibit, delay or otherwise interfere with the acquisition of a 340B drug by, or delivery of a 340B drug to, a covered entity or contract pharmacy, or place any conditions on the acquisition or receipt, unless the acquisition or receipt is prohibited by Federal law.(b) Conditions.--A manufacturer, or an agent or affiliate of a manufacturer, may not, either directly or indirectly, require a covered entity to submit any claims or utilization data as a condition for allowing the acquisition of a 340B drug by, or delivery of a 340B drug to, a covered entity or contract pharmacy unless the claims or utilization data submission is required by Federal law.Section 7. Penalties.(a) Enforcement.--(1) The Insurance Department shall investigate complaints alleging violations and enforce sections 3 and 5 of this act and may examine or audit the books and records of a pharmacy benefit manager, covered insurer or related party to determine if the party is compliant with this act and issue any subpoenas needed to carry out enforcement and oversight under this act.(2) The commission of any act that violates section 6 shall constitute an unlawful practice within the meaning of the act of December 17, 1968 (P.L.1224, No.387), known as the Unfair Trade Practices and Consumer Protection Law. The Office of Attorney General shall have jurisdiction, consistent with the provisions of the Unfair Trade Practices and Consumer Protection Law, to enforce the provisions of section 6 and to promulgate regulations implementing the provisions of section 6.20260SB1481PN1965 - 7 - 123456789101112131415161718192021222324252627282930 (3) The department may promulgate regulations consistent with section 6 and may investigate a complaint of a violation of section 6 by an individual or entity licensed by or registered with the department to impose discipline on, or suspend or revoke the license or registration of, any individual or entity licensed by the department that is in violation of section 6, and to issue any subpoenas needed to carry out enforcement and oversight under this act.(b) Fines.--(1) The Insurance Department shall impose, upon written notice, a fine on a pharmacy benefit manager or covered insurer that violates the provisions of this act in accordance with the following:(i) For a pharmacy benefit manager or covered insurer that violates a provision of section 3 or a provision of section 5(a)(1), an amount of $1,000 per wrongfully denied claim or improperly paid claim.(ii) For a pharmacy benefit manager or covered insurer that violates section 5(a)(2), an amount of $1,000 per day for each excluded pharmacy.(2) The Office of Attorney General shall impose, upon written notice, a fine on a manufacturer, or an agent or affiliate of the manufacturer, that violates section 6, in an amount of $50,000 per each violation, up to an aggregate fine of $10,000,000 per year for multiple violations. Each package of 340B drug determined to be subject to a prohibited act under section 6 shall constitute a separate violation under section 6.(c) Suspension.--(1) The Insurance Department shall suspend the ability 20260SB1481PN1965 - 8 - 123456789101112131415161718192021222324252627282930 of a pharmacy benefit manager or covered insurer, including a Medicaid managed care organization, to conduct business in this Commonwealth if a violation under section 3 or 5 is not rectified within 30 days of the date when the written notice is sent to the pharmacy benefit manager or covered insurer under subsection (b).(2) The Office of Attorney General may seek appropriate relief to prohibit a manufacturer, or an agent or affiliate of a manufacturer, from conducting business in this Commonwealth if a violation under section 6 is not rectified within 30 days of the date when the written notice is sent to the manufacturer, or an agent or affiliate of the manufacturer, under subsection (b).(d) Contracts.--A contract term in a contract entered into on or after the effective date of this subsection that violates section 3 or 5 shall be null and void.(e) Injunctive relief.--A covered entity or contract pharmacy may immediately seek injunctive relief in Commonwealth Court to enforce the provisions of this act.Section 8. Rebuttable presumption.(a) Establishment.--If a covered entity or contract pharmacy establishes that a 340B drug, claim for a 340B drug, covered entity or contract pharmacy was subject to a reimbursement rate, term, condition, restriction or other treatment that differs from the reimbursement rate, term, condition, restriction or treatment applicable to the same drug when not purchased under the 340B program, a claim for the same drug when not purchased under the 340B program or a similarly situated entity or pharmacy that does not participate in the 340B program, there shall be a rebuttable presumption that the difference in 20260SB1481PN1965 - 9 - 123456789101112131415161718192021222324252627282930 treatment was based on participation in the 340B program or the status of the drug or claim as a 340B drug or claim.(b) Rebuttal.--A pharmacy benefit manager, covered insurer, manufacturer or other person subject to this act may rebut the presumption under subsection (a) by demonstrating that the difference in treatment resulted from a legitimate factor unrelated to participation in the program established under section 340B of the Public Health Service Act.(c) Construction.--Nothing in this section shall be construed to establish a defense to conduct otherwise expressly prohibited under this act.Section 9. Construction.(a) Federal law.--Nothing in this act shall be construed or applied to be less restrictive than any Federal law as to any person or entity regulated by this act.(b) Conflict.--Nothing in this act shall be construed or applied to be in conflict with any of the following:(1) Applicable Federal law and related regulations, including 42 U.S.C. Ch. 7 Subch. XI Pt. E. (relating to price negotiation program to lower prices for certain high-priced single source drugs).(2) Other laws of this Commonwealth if the law is compatible with applicable Federal law, provided that this act shall be interpreted to provide greater protection for covered entities and contract pharmacies than the act of November 21, 2016 (P.L.1318, No.169), known as the Pharmacy Benefit Reform Act, if both acts are applicable.(c) Limited distribution of drug.--Limited distribution of a drug required under 21 U.S.C. § 355-1 (relating to risk evaluation and mitigation strategies) shall not be construed as 20260SB1481PN1965 - 10 - 123456789101112131415161718192021222324252627282930 a violation of this act.Section 10. Effective date.This act shall take effect in 90 days.20260SB1481PN1965 - 11 - 123

Official text from the Pennsylvania Legislature. Formatting has been adapted for reading on Ratifi.